Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168484 | 0.85 | GAA (0.37) | GAAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL31074506 | 0.85 | GAA (0.46) | GAAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL25746423 | 0.83 | GAA (0.35) | GAAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL174551 | 0.83 | GAA (0.35) | GAAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL25746426 | 0.82 | GAA (0.37) | GAAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL20150224 | 0.81 | GAA (0.34) | GAAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL25746422 | 0.79 | GAA (0.40) | GAAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL29457783 | 0.77 | GAA (0.39) | GAAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL25408348 | 0.76 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL29644058 | 0.75 | CNR2 (0.39) | ALDH1A1MEN1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112812105-A | Aminopyridyloxypyrazole derivative and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | GAA 1899/4885ALDH1A1 4827/4885MEN1 2491/4885 |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | GAA 1899/4885ALDH1A1 4827/4885MEN1 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.